Table 3.

Relationship between overexpression of the FLT3 transcript and clinical characteristics in 91 AML cases without FLT3/ITD




Total, N = 91

FLT3 transcripts more than 200 000 copies/μg RNA, N = 5

FLT3 transcripts less than or equal to 200 000 copies/μg RNA, N = 86
Age, y (range)  48 (15-85)   43 (21-69)   48 (15-85)  
    Older than 60 y, n   27   2   25  
WBC count, × 109/L (range)  23.4 (1.2-211)   56.1 (24.7-197.4)   22.2 (1.2-211)  
    More than 100 × 109/L, n   14   1   13  
FAB    
    M0   2   1   1  
    M1   19   1   18  
    M2   45   2   43  
    M4   18   1   17  
    M5   6   0   6  
    M6   1   0   1  
    M7   0   0   0  
Cytogenetics    
    Favorable   20   1   19  
        t(8; 21)   17   1   16  
        inv(16)   3   0   3  
    Intermediate   67   4   63  
    Poor   4   0   4  
        t(9; 22)   2   0   2  
        del(7)   2   0   2  
Outcome    
    CR   71   2   69  
    Failure   20   3   17  
MLL-TD mutation   9   2   7  
p53 gene mutation   2   0   2  
N-RAS gene mutation   14   1   13  
FLT3/D835 mutation
 
5
 
0
 
5
 



Total, N = 91

FLT3 transcripts more than 200 000 copies/μg RNA, N = 5

FLT3 transcripts less than or equal to 200 000 copies/μg RNA, N = 86
Age, y (range)  48 (15-85)   43 (21-69)   48 (15-85)  
    Older than 60 y, n   27   2   25  
WBC count, × 109/L (range)  23.4 (1.2-211)   56.1 (24.7-197.4)   22.2 (1.2-211)  
    More than 100 × 109/L, n   14   1   13  
FAB    
    M0   2   1   1  
    M1   19   1   18  
    M2   45   2   43  
    M4   18   1   17  
    M5   6   0   6  
    M6   1   0   1  
    M7   0   0   0  
Cytogenetics    
    Favorable   20   1   19  
        t(8; 21)   17   1   16  
        inv(16)   3   0   3  
    Intermediate   67   4   63  
    Poor   4   0   4  
        t(9; 22)   2   0   2  
        del(7)   2   0   2  
Outcome    
    CR   71   2   69  
    Failure   20   3   17  
MLL-TD mutation   9   2   7  
p53 gene mutation   2   0   2  
N-RAS gene mutation   14   1   13  
FLT3/D835 mutation
 
5
 
0
 
5
 

Mean (minimum to maximum) values are indicated for age and WBC count. Number of cases is shown by age (> 60 years), WBC count (> 100 × 109/L), FAB, cytogenetics, outcome, and gene mutations. The favorable risk group was defined by t(8;21) or inv(16), the poor risk group by t(9;22) or del(7), and the intermediate risk group by normal or other karyotypes and karyotype unknown. CR indicates complete remission.

or Create an Account

Close Modal
Close Modal